


**Highlights of This Issue 2767****REVIEW**

- 2769** **Effects of *BRAF* Mutations and *BRAF* Inhibition on Immune Responses to Melanoma**  
 Kristina M. Ilieva, Isabel Correa, Debra H. Josephs, Panagiotis Karagiannis, Isioma U. Egbuniwe, Michiala J. Cafferkey, James F. Spicer, Mark Harries, Frank O. Nestle, Katie E. Lacy, and Sophia N. Karagiannis

**SMALL MOLECULE THERAPEUTICS**

- 2784** **Vorinostat Downregulates CD30 and Decreases Brentuximab Vedotin Efficacy in Human Lymphocytes**  
 Zainul S. Hasanali, Elliot M. Epner, David J. Feith, Thomas P. Loughran Jr, and Clare E. Sample
- 2793** **Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to *BRAF* Inhibitors and Overcomes Resistance to Dual *BRAF* and *MEK* Inhibition in Melanoma Models**  
 Tomoko Smyth, Kim H.T. Paraiso, Keisha Hearn, Ana M. Rodriguez-Lopez, Joanne M. Munck, H. Eirik Haarberg, Vernon K. Sondak, Neil T. Thompson, Mohammad Azab, John F. Lyons, Keiran S.M. Smalley, and Nicola G. Wallis
- 2805** **Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport**  
 Becky M. Bola, Amy L. Chadwick, Filippos Michopoulos, Kathryn G. Blount, Brian A. Telfer, Kaye J. Williams, Paul D. Smith, Susan E. Critchlow, and Ian J. Stratford
- 2817** **Antitumor Effects of a Novel Small Molecule Targeting PCNA Chromatin Association in Prostate Cancer**  
 Kelsey L. Dillehay, Shan Lu, and Zhongyun Dong
- 2827** **The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer**  
 Naokazu Ibuki, Mazyar Ghaffari, Hadas Reuveni, Mitali Pandey, Ladan Fazli, Haruhito Azuma, Martin E. Gleave, Alexander Levitzki, and Michael E. Cox

- 2840** **Combination Therapy for *KIT*-Mutant Mast Cells: Targeting Constitutive NFAT and *KIT* Activity**  
 Alison C. Macleod, Lillian R. Klug, Janice Patterson, Diana J. Griffith, Carol Beadling, Ajia Town, and Michael C. Heinrich
- 2852** **PET Imaging of  $\beta$ -Glucuronidase Activity by an Activity-Based  $^{124}\text{I}$ -Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy**  
 Yu-Cheng Su, Ta-Chun Cheng, Yu-Ling Leu, Steve R. Roffler, Jaw-Yuan Wang, Chih-Hung Chuang, Chien-Han Kao, Kai-Chuan Chen, Hsin-Ell Wang, and Tian-Lu Cheng
- 2864** **Paclitaxel-Loaded PEG-PE-Based Micellar Nanopreparations Targeted with Tumor-Specific Landscape Phage Fusion Protein Enhance Apoptosis and Efficiently Reduce Tumors**  
 Tao Wang, Shenghong Yang, Leslie A. Mei, Chirag K. Parmar, James W. Gillespie, Kulkarni P. Praveen, Valery A. Petrenko, and Vladimir P. Torchilin
- 2876** **Therapeutic Silencing of *KRAS* Using Systemically Delivered siRNAs**  
 Chad V. Pecot, Sherry Y. Wu, Seth Bellister, Justyna Filant, Rajesha Rupaimoole, Takeshi Hisamatsu, Rajat Bhattacharya, Anshumaan Maharaj, Salma Azam, Cristian Rodriguez-Aguayo, Archana S. Nagaraja, Maria Pia Morelli, Kshipra M. Gharpure, Trent A. Waugh, Vianey Gonzalez-Villasana, Behrouz Zand, Heather J. Dalton, Scott Kopetz, Gabriel Lopez-Berestein, Lee M. Ellis, and Anil K. Sood
- 2886** ***In Vitro* and *In Vivo* Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells**  
 Girija Dasmahapatra, Hiral Patel, Johnathan Friedberg, Steven N. Quayle, Simon S. Jones, and Steven Grant
- 2898** **Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis**  
 Le T. Duong, Gregg A. Wesolowski, Patrick Leung, Renata Oballa, and Maureen Pickarski

# Table of Contents

- 2910** **Alectinib Shows Potent Antitumor Activity against *RET*-Rearranged Non–Small Cell Lung Cancer**  
Tatsushi Kodama, Toshiyuki Tsukaguchi, Yasuko Satoh, Miyuki Yoshida, Yoshiaki Watanabe, Osamu Kondoh, and Hiroshi Sakamoto
- 2919** **NT113, a Pan-ERBB Inhibitor with High Brain Penetration, Inhibits the Growth of Glioblastoma Xenografts with *EGFR* Amplification**  
Yasuyuki Yoshida, Tomoko Ozawa, Tsun-Wen Yao, Wang Shen, Dennis Brown, Andrew T. Parsa, Jeffrey J. Raizer, Shi-Yuan Cheng, Alexander H. Stegh, Andrew P. Mazar, Francis J. Giles, Jann N. Sarkaria, Nicholas Butowski, Theodore Nicolaides, and C. David James
- 2930** **Withanone-Rich Combination of Ashwagandha Withanolides Restricts Metastasis and Angiogenesis through hnRNP-K**  
Ran Gao, Navjot Shah, Jung-Sun Lee, Shashank P. Katiyar, Ling Li, Eonju Oh, Durai Sundar, Chae-Ok Yun, Renu Wadhwa, and Sunil C. Kaul
- 2941** **Marine Sponge *Cribrorchalina vasculum* Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma**  
Ana Zovko, Kristina Viktorsson, Petra Hååg, Dimitry Kovalerchick, Katarina Färnegårdh, Andrea Alimonti, Micha Ilan, Shmuel Carmeli, and Rolf Lewensohn
- 2955** **The Combination of Cannabidiol and  $\Delta^9$ -Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model**  
Katherine A. Scott, Angus G. Dalglish, and Wai M. Liu
- 2968** **Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound**  
Vitali Alexeev, Elizabeth Lash, April Aguiard, Laura Corsini, Avi Bitterman, Keith Ward, Adam P. Dicker, Alban Linnenbach, and Ulrich Rodeck
- 2978** **Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance**  
Aki Aoyama, Ryohei Katayama, Tomoko Oh-hara, Shigeo Sato, Yasushi Okuno, and Naoya Fujita

## LARGE MOLECULE THERAPEUTICS

- 2991** **SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer**  
Django Sussman, Leia M. Smith, Martha E. Anderson, Steve Duniho, Joshua H. Hunter, Heather Kostner, Jamie B. Miyamoto, Albina Nesterova, Lori Westendorf, Heather A. Van Epps, Nancy Whiting, and Dennis R. Benjamin
- 3001** **Antibody against Granulin–Epithelin Precursor Sensitizes Hepatocellular Carcinoma to Chemotherapeutic Agents**  
Nicholas C.L. Wong, Phyllis F.Y. Cheung, Chi Wai Yip, Kui Fat Chan, Irene Oi-Lin Ng, Sheung Tat Fan, and Siu Tim Cheung

## CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 3013** **CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway**  
Naoya Saito, Keiichi Sakakibara, Takuji Sato, Jonathan M. Friedman, Donald W. Kufe, Daniel D. VonHoff, and Takumi Kawabe
- 3024** **Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions**  
Yohei Mineharu, Neha Kamran, Pedro R. Lowenstein, and Maria G. Castro
- 3037** **Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer**  
Wei Wen, Wei Liang, Jun Wu, Claudia M. Kowolik, Ralf Buettner, Anna Scuto, Meng-Yin Hsieh, Hao Hong, Christine E. Brown, Stephen J. Forman, David Horne, Robert Morgan, Mark Wakabayashi, Thanh H. Dellinger, Ernest S. Han, John H. Yim, and Richard Jove
- 3049** **RRAD Promotes EGFR-Mediated STAT3 Activation and Induces Temozolomide Resistance of Malignant Glioblastoma**  
Seon-Yong Yeom, Do-Hyun Nam, and Chaehwa Park

# Table of Contents

- 3062** **A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation**  
Heidi M. Ott, Alan P. Graves, Melissa B. Pappalardi, Michael Huddleston, Wendy S. Halsey, Ashley M. Hughes, Arthur Groy, Edward Dul, Yong Jiang, Yuchen Bai, Roland Annan, Sharad K. Verma, Steven D. Knight, Ryan G. Kruger, Dashyant Dhanak, Benjamin Schwartz, Peter J. Tummino, Caretha L. Creasy, and Michael T. McCabe
- 3074** **The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression**  
Jeong Min Kim, Hei-Cheul Jeung, Sun Young Rha, Eun Jeong Yu, Tae Soo Kim, You Keun Shin, Xianglan Zhang, Kyu Hyun Park, Seung Woo Park, Hyun Cheol Chung, and Garth Powis
- 3086** **Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression**  
Gan Yu, Weimin Yao, Kiranmai Gumireddy, Anping Li, Ji Wang, Wei Xiao, Ke Chen, Haibing Xiao, Heng Li, Kun Tang, Zhangqun Ye, Qihong Huang, and Hua Xu
- 3098** **MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations**  
Shunsuke Sogabe, Yosuke Togashi, Hiroaki Kato, Akihiro Kogita, Takuro Mizukami, Yoichi Sakamoto, Eri Banno, Masato Terashima, Hidetoshi Hayashi, Marco A. de Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Takushi Yasuda, Yoshifumi Takeyama, Kiyotaka Okuno, and Kazuto Nishio
- 3107** **Doxycycline as an Inhibitor of the Epithelial-to-Mesenchymal Transition and Vasculogenic Mimicry in Hepatocellular Carcinoma**  
Jie Meng, Baocun Sun, Xiulan Zhao, Danfang Zhang, Xueming Zhao, Qiang Gu, Xueyi Dong, Nan Zhao, Peimei Liu, and Yanrong Liu
- 3123** **Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer**  
Bella S. Guerrouahen, Jennifer Pasquier, Nadine Abu Kaoud, Mahtab Maleki, Marie-Claude Beauchamp, Amber Yasmeen, Pegah Ghiabi, Raphael Lis, Fabien Vidal, Ahmed Saleh, Walter H. Gotlieb, Shahin Rafii, and Arash Rafii
- 3137** **miR200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer**  
Hua Sui, Guo-Xiang Cai, Shu-Fang Pan, Wan-Li Deng, Yu-Wei Wang, Zhe-Sheng Chen, San-Jun Cai, Hui-Rong Zhu, and Qi Li
- 3152** **miR141–CXCL1–CXCR2 Signaling–Induced Treg Recruitment Regulates Metastases and Survival of Non–Small Cell Lung Cancer**  
Mingming Lv, Yujun Xu, Ruijing Tang, Jing Ren, Sunan Shen, Yueqiu Chen, Baorui Liu, Yayi Hou, and Tingting Wang
- 3163** **Involvement of microRNA-24 and DNA Methylation in Resistance of Nasopharyngeal Carcinoma to Ionizing Radiation**  
Sumei Wang, Rong Zhang, Francois X. Claret, and Huiling Yang
- 3175** **Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents**  
Prasanth Ganesan, Stacy Moulder, J. Jack Lee, Filip Janku, Vicente Valero, Ralph G. Zinner, Aung Naing, Siqing Fu, Apostolia M. Tsimberidou, David Hong, Bettzy Stephen, Philip Stephens, Roman Yelensky, Funda Meric-Bernstam, Razelle Kurzrock, and Jennifer J. Wheler
- COMPANION DIAGNOSTICS AND CANCER BIOMARKERS**
- 3185** **miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer**  
Hailin Tang, Peng Liu, Lu Yang, Xinhua Xie, Feng Ye, Mingqing Wu, Xiaoping Liu, Bo Chen, Lijuan Zhang, and Xiaoming Xie
- 3198** **Coordinate Hyperactivation of Notch1 and Ras/MAPK Pathways Correlates with Poor Patient Survival: Novel Therapeutic Strategy for Aggressive Breast Cancers**  
Suruchi Mittal, Ankur Sharma, Sai A. Balaji, Manju C. Gowda, Rajan R. Dighe, Rekha V. Kumar, and Annapoorni Rangarajan

# Table of Contents

**3210 Clinical Utility of a Blood-Based BRAF<sup>V600E</sup> Mutation Assay in Melanoma**

David J. Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, Aislyn P. Schalck, Laleh Montaser-Kouhsari, Alireza Sepehr, Donald P. Lawrence, David F. McDermott, Rachel Cohen, Alexander Carlson, Jennifer A. Wargo, Ryan Merritt, Virginia J. Seery, F. Stephen Hodi, Anasuya Gunturi, Dennie Fredrick, Michael B. Atkins, A. John Iafrate, Keith T. Flaherty, James W. Mier, and Ryan J. Sullivan

**3219 Utilization of the *Eμ-Myc* Mouse to Model Heterogeneity of Therapeutic Response**

Rachel E. Rempel, Xiaolei Jiang, Paul Fullerton, Tuan Zea Tan, Jieru Ye, Jieying Amelia Lau, Seiichi Mori, Jen-Tsan Chi, Joseph R. Nevins, and Daphne R. Friedman

## MODELS AND TECHNOLOGIES

**3230 Cancer *In Silico* Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes**



F. Anthony San Lucas, Jerry Fowler, Kyle Chang, Scott Kopetz, Eduardo Vilar, and Paul Scheet


**3241 Acknowledgment to Reviewers**

 AC icon indicates Author Choice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

This is an image of the predicted binding model in which tivantinib (ARQ197) binds to the colchicine binding site of tubulin, calculated by GOLD docking program. Top-scored binding pose of tivantinib (magenta) to tubulin was overlaid on the structure of colchicine (cyan)-tubulin complex. Tivantinib was originally identified as a c-MET inhibitor and is currently under clinical evaluation. However, recent reports suggest that its cytotoxic activity was caused by microtubule dysfunction. Aoyama and colleagues show that tivantinib competitively inhibited binding of colchicine to purified tubulin. For more details, see the article by Aoyama and colleagues on page 2978.



# Molecular Cancer Therapeutics

13 (12)

*Mol Cancer Ther* 2014;13:2767-3245.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/13/12>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://mct.aacrjournals.org/content/13/12>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.